Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Diabetes Drugs Market Portraiture
2.1.1. Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
2.1.2. Global Diabetes Drugs Market, by Geography, 2016 (US$ Bn)
Chapter 3. Diabetes Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Diabetes: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography, 2016
3.6. Value Chain Analysis
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
4.1. Overview
4.2. Attractive Investment Proposition, by Type of Therapy, 2016
4.3. Insulin
4.4. Oral Hypoglycemic Drugs (anti-diabetes drugs)
4.5. Non-insulin Injectable Anti-diabetes Drugs
4.6. Others
4.7. Phase III (Market estimations by 2025)
4.7.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
4.7.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
4.7.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
4.7.4. Others
4.8. Tabular Presentation of Phase II (Qualitative Information)
4.9. Tabular Presentation of Phase Phase I (Qualitative Information)
Chapter 5. Global Diabetes Drugs Market, by Geography, 2015 – 2025
5.1. Overview
5.2. North America Diabetes Drugs Market Analysis, 2015 – 2025
5.2.1. North America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.2.2. North America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Diabetes Drugs Market Analysis, 2015 – 2025
5.3.1. Europe Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.3.2. Europe Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Spain
5.3.2.5. Italy
5.3.2.6. Rest of Europe
5.4. Asia Pacific Diabetes Drugs Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.4.2. Asia Pacific Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.4.2.1. China
5.4.2.2. India
5.4.2.3. Japan
5.4.2.4. Rest of APAC
5.5. Latin America Diabetes Drugs Market Analysis, 2015 – 2025
5.5.1. Latin America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.5.2. Latin America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Diabetes Drugs Market Analysis, 2015 – 2025
5.6.1. MEA Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.6.2. MEA Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1.1. AstraZeneca plc
6.1.2. Business Description
6.1.3. Financial Information (Subject to data availability)
6.1.4. Application Portfolio
6.1.5. Key Developments
6.2. Biocon Limited
6.3. Boston Therapeutics, Inc.
6.4. Cadila Healthcare
6.5. Eli Lilly and Company
6.6. GlaxoSmithKline plc
6.7. Johnson & Johnson
6.8. Lupin Limited
6.9. Merck & Co., Inc.
6.10. Novartis International AG
6.11. Pfizer Inc.
6.12. Ranbaxy Laboratories Limited
6.13. Sanofi S.A.
6.14. Takeda Pharmaceutical Company Ltd.
List of Figures
FIG. 1 Diabetes Drugs: Market Segmentation
FIG. 2 Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
FIG. 3 Global Diabetes Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Value Chain Analysis: Global Diabetes Drugs Market
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Insulin Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Oral hypoglycemic drugs (anti-diabetes drugs) Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Non-insulin injectable anti-diabetes drugs Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Other Diabetes Drugs Types Market, 2015 – 2025 (US$ Bn)
FIG. 11 U.S. Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 12 Canada Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 13 U.K. Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 14 Germany Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 15 France Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 16 Spain Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 17 Italy Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 18 Rest of Europe Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 19 China Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 20 India Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 21 Japan Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 22 Rest of Asia Pacific Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 23 Brazil Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 24 Mexico Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 25 Rest of Latin America Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 26 GCC Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 27 Rest of Middle East and Africa Diabetes Drugs Market, 2015 – 2025 (US$ Bn)
List of Tables
TABLE 1 Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 2 Global Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 3 North America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 4 North America Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 Europe Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 6 Europe Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 7 Asia Pacific Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 8 Asia Pacific Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 9 Latin America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 10 Latin America Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 11 Middle East and Africa Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
TABLE 12 Middle East and Africa Diabetes Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 13 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Biocon Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Boston Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Cadila Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Lupin Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Takeda Pharmaceutical Company Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)